PFE vs. GS

Last updated Jun 6, 2026

PFE (Pfizer Inc.) and GS (The Goldman Sachs Group, Inc.) are both stocks. PFE operates in Drug Manufacturers - General (Healthcare), while GS operates in Capital Markets (Financial Services). Over the past 10 years, PFE returned 2.09%/yr vs 23.45%/yr for GS. At a 0.31 correlation, their price movements are largely independent.

Performance

PFE vs. GS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pfizer Inc. (PFE) and The Goldman Sachs Group, Inc. (GS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PFE achieves a 8.09% return, which is significantly lower than GS's 19.31% return. Over the past 10 years, PFE has underperformed GS with an annualized return of 2.09%, while GS has yielded a comparatively higher 23.45% annualized return.

PFE

• 1D: 1.36%
• 1M: -0.23%
• YTD: 8.09%
• 6M: 3.39%
• 1Y: 20.50%
• 3Y*: -6.48%
• 5Y*: -2.98%
• 10Y*: 2.09%

GS

• 1D: -4.94%
• 1M: 11.30%
• YTD: 19.31%
• 6M: 22.72%
• 1Y: 74.88%
• 3Y*: 50.51%
• 5Y*: 24.53%
• 10Y*: 23.45%

*Multi-year figures are annualized to reflect compound growth (CAGR)

PFE vs. GS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PFE Pfizer Inc.	8.09%	0.65%	-2.22%	-41.26%	-10.41%	66.70%	3.07%	-6.91%	24.82%	15.90%
GS The Goldman Sachs Group, Inc.	19.31%	56.64%	52.03%	15.91%	-7.87%	47.61%	17.45%	40.48%	-33.53%	7.73%

Correlation

The correlation between PFE and GS is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.17
Correlation (3Y) Calculated over the trailing 3-year period	0.24
Correlation (5Y) Calculated over the trailing 5-year period	0.23
Correlation (10Y) Calculated over the trailing 10-year period	0.26
Correlation (All Time) Calculated using the full available price history since May 5, 1999	0.31

The correlation between PFE and GS shifts across timeframes, from 0.17 (1 year) to 0.31 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap PFE : $149.24B GS : $319.91B
EPS PFE : $1.31 GS : $57.41
PE Ratio PFE : 19.85 GS : 18.09
PEG Ratio PFE : 0.36 GS : 2.34
PS Ratio PFE : 2.35 GS : 2.95
PB Ratio PFE : 1.66 GS : 2.60
Total Revenue (TTM) PFE : $63.32B GS : $110.77B
Gross Profit (TTM) PFE : $43.91B GS : $61.53B
EBITDA (TTM) PFE : $16.94B GS : $24.94B

Return for Risk

PFE vs. GS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PFE

PFE Risk / Return Rank: 67
PFE Sharpe Ratio Rank: 68
PFE Sortino Ratio Rank: 64
PFE Omega Ratio Rank: 61
PFE Calmar Ratio Rank: 72
PFE Martin Ratio Rank: 70

GS

GS Risk / Return Rank: 90
GS Sharpe Ratio Rank: 93
GS Sortino Ratio Rank: 90
GS Omega Ratio Rank: 90
GS Calmar Ratio Rank: 87
GS Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PFE vs. GS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and The Goldman Sachs Group, Inc. (GS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PFE	GS	Difference
Sharpe ratio: Return per unit of total volatility	0.86	2.68	-1.82
Sortino ratio: Return per unit of downside risk	1.43	3.28	-1.85
Omega ratio: Gain probability vs. loss probability	1.17	1.43	-0.26
Calmar ratio: Return relative to maximum drawdown	1.79	3.88	-2.08
Martin ratio: Return relative to average drawdown	3.68	12.98	-9.30
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PFE vs. GS - Sharpe Ratio Comparison

The current PFE Sharpe Ratio is 0.86, which is lower than the GS Sharpe Ratio of 2.68. The chart below compares the historical Sharpe Ratios of PFE and GS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	PFE	GS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.86	2.68	-1.82
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.12	0.88	-1.00
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.09	0.79	-0.70
Sharpe Ratio (All Time) Calculated using the full available price history	0.33	0.33	0.00

Drawdowns

PFE vs. GS - Drawdown Comparison

The maximum PFE drawdown since its inception was -69.24%, smaller than the maximum GS drawdown of -78.84%. Use the drawdown chart below to compare losses from any high point for PFE and GS.

Drawdown Indicators

	PFE	GS	Difference
Max Drawdown Largest peak-to-trough decline	-69.24%	-78.84%	+9.60%
Max Drawdown (1Y) Largest decline over 1 year	-11.47%	-19.42%	+7.95%
Max Drawdown (3Y) Largest decline over 3 years	-40.75%	-30.90%	-9.85%
Max Drawdown (5Y) Largest decline over 5 years	-58.96%	-32.84%	-26.12%
Max Drawdown (10Y) Largest decline over 10 years	-58.96%	-48.75%	-10.21%
Current Drawdown Current decline from peak	-46.03%	-4.94%	-41.09%
Average Drawdown Average peak-to-trough decline	-22.89%	-22.62%	-0.27%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.59%	5.79%	-0.20%

Volatility

PFE vs. GS - Volatility Comparison

The current volatility for Pfizer Inc. (PFE) is 4.50%, while The Goldman Sachs Group, Inc. (GS) has a volatility of 10.72%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than GS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PFE	GS	Difference
Volatility (1M) Calculated over the trailing 1-month period	4.50%	10.72%	-6.22%
Volatility (6M) Calculated over the trailing 6-month period	14.66%	23.01%	-8.35%
Volatility (1Y) Calculated over the trailing 1-year period	23.92%	28.11%	-4.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.50%	28.03%	-2.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.88%	29.83%	-5.95%

Dividends

PFE vs. GS - Dividend Comparison

PFE's dividend yield for the trailing twelve months is around 6.61%, more than GS's 1.64% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GS The Goldman Sachs Group, Inc.	1.64%	1.59%	2.01%	2.72%	2.62%	1.70%	1.90%	1.80%	1.89%	1.14%	1.09%	1.41%
PFE Pfizer Inc.	6.61%	6.91%	6.33%	5.70%	3.12%	2.64%	3.92%	3.68%	3.12%	3.53%	3.69%	3.47%

Financials

PFE vs. GS - Profitability Comparison

The chart below illustrates the profitability comparison between Pfizer Inc. and The Goldman Sachs Group, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.

GS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a gross profit of 16.91B and revenue of 17.23B. Therefore, the gross margin over that period was 98.2%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.

GS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported an operating income of 6.49B and revenue of 17.23B, resulting in an operating margin of 37.7%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.

GS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Goldman Sachs Group, Inc. reported a net income of 5.63B and revenue of 17.23B, resulting in a net margin of 32.7%.

Frequently Asked Questions

Can I hold both PFE and GS in my portfolio?

PFE and GS have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PFE or GS?

GS has higher volatility (10.72%) compared to PFE (4.50%). In terms of maximum drawdown, PFE dropped -69.24% vs GS's -78.84%.

Which has better risk-adjusted returns?

GS currently has the higher Sharpe Ratio (2.68 vs 0.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.